{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:57:55Z","timestamp":1761238675101,"version":"3.40.5"},"reference-count":165,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,4,24]]},"abstract":"<jats:sec><jats:title\/><jats:p>Toxoplasma gondii is a prevalent parasitic pathogen that infected over one-third of the global population. Toxoplasmosis is diagnosed by isolating the parasite and detecting host antibodies. In contrast, the main problem with diagnosis relates to the sensitivity and specificity of the tests. Currently, treatment with pyrimethamine and sulfadiazine is recommended, despite their side effects and toxicity to humans. Moreover, the absence of a vaccine to completely protect against this infection is the main obstacle to the effective treatment and prevention of toxoplasmosis. Recently, nanoparticles and nanomaterials have been studied as delivery systems for the immunization and treatment of T. gondii infections. One of the most important applications of liposomes is drug and vaccine delivery, due to their biodegradability, low inherent toxicity, and immunogenicity. Liposomes are flexible delivery systems and immunological adjuvants able not only to load diverse antigens, such as proteins, peptides, nucleic acids, and carbohydrates but also to combine them with immunostimulators. Liposomes have the incredible potential within the development of modern types of vaccines and numerous endeavors have been made to improve the effectiveness of vaccines in recent years. In this review, we concentrate on the viable targeting strategies of liposome-based vaccine delivery systems to prevent, control and treat toxoplasmosis.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666191023151423","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T14:45:54Z","timestamp":1571841954000},"page":"541-558","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems"],"prefix":"10.2174","volume":"21","author":[{"given":"Yaghob","family":"Azadi","sequence":"first","affiliation":[{"name":"Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Ahmadpour","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-3633","authenticated-orcid":true,"given":"Amirhossein","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ijpara.2009.02.004","volume":"39","author":"Weiss L.M.","year":"2009","unstructured":"Weiss L.M.; Dubey J.P.; Toxoplasmosis: A history of clinical observations. Int J Parasitol 2009,39(8),895-901","journal-title":"Int J Parasitol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1590\/S0074-02762009000200033","volume":"104","author":"Tenter A.M.","year":"2009","unstructured":"Tenter A.M.; Toxoplasma gondii in animals used for human consumption. Mem Inst Oswaldo Cruz 2009,104(2),364-369","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jiph.2015.06.006","volume":"9","author":"Sharif M.","year":"2016","unstructured":"Sharif M.; Daryani A.; Ebrahimnejad Z.; Seroprevalence of anti-Toxoplasma IgG and IgM among individuals who were referred to medical laboratories in Mazandaran province, northern Iran. J Infect Public Health 2016,9(1),75-80","journal-title":"J Infect Public Health"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.actatropica.2014.05.015","volume":"137","author":"Daryani A.","year":"2014","unstructured":"Daryani A.; Sarvi S.; Aarabi M.; Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta Trop 2014,137,185-194","journal-title":"Acta Trop"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1756-3305-5-271","volume":"5","author":"Galvan-Ramirez Mde L.","year":"2012","unstructured":"Galvan-Ramirez Mde L.; Troyo R.; Roman S.; Calvillo-Sanchez C.; Bernal-Redondo R.; A systematic review and meta-analysis of Toxoplasma gondii infection among the Mexican population. Parasit Vectors 2012,5(1),271","journal-title":"Parasit Vectors"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3855\/jidc.4796","volume":"8","author":"Ahmadpour E.","year":"2014","unstructured":"Ahmadpour E.; Daryani A.; Sharif M.; Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries 2014,8(12),1503-1510","journal-title":"J Infect Dev Ctries"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0147-9571(02)00058-9","volume":"26","author":"Bhopale G.M.","year":"2003","unstructured":"Bhopale G.M.; Pathogenesis of toxoplasmosis. Comp Immunol Microbiol Infect Dis 2003,26(4),213-222","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.tmrv.2016.03.002","volume":"30","author":"Foroutan-Rad M.","year":"2016","unstructured":"Foroutan-Rad M.; Majidiani H.; Dalvand S.; Toxoplasmosis in blood donors: a systematic review and meta-analysis. Transfus Med Rev 2016,30(3),116-122","journal-title":"Transfus Med Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.clinthera.2008.10.021","volume":"30","author":"Iaccheri B.","year":"2008","unstructured":"Iaccheri B.; Fiore T.; Papadaki T.; Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review. Clin Ther 2008,30(11),2069-2074","journal-title":"Clin Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s12639-014-0623-3","volume":"40","author":"Rezaei F.","year":"2016","unstructured":"Rezaei F.; Ebrahimzadeh M.A.; Daryani A.; Sharif M.; Ahmadpour E.; Sarvi S.; The inhibitory effect of cromolyn sodium and ketotifen on Toxoplasma gondii entrance into host cells in vitro and in vivo. J Parasit Dis 2016,40(3),1001-1005","journal-title":"J Parasit Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fmicb.2017.00025","volume":"8","author":"Montazeri M.","year":"2017","unstructured":"Montazeri M.; Sharif M.; Sarvi S.; Mehrzadi S.; Ahmadpour E.; Daryani A.; A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006\u20132016). Front Microbiol 2017,8,25","journal-title":"Front Microbiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/2211738503666150709173905","volume":"3","author":"Nekkanti V.","year":"2015","unstructured":"Nekkanti V.; Kalepu S.; Recent advances in liposomal drug delivery: a review. Pharm Nanotechnol 2015,3(1),35-55","journal-title":"Pharm Nanotechnol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1017\/S0031182014000481","volume":"141","author":"Hiszczy\u0144ska-Sawicka E.","year":"2014","unstructured":"Hiszczy\u0144ska-Sawicka E.; Gatkowska J.M.; Grzybowski M.M.; D\u0142ugo\u0144ska H.; Veterinary vaccines against toxoplasmosis. Parasitology 2014,141(11),1365-1378","journal-title":"Parasitology"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0169-4758(93)90236-9","volume":"9","author":"Buxton D.","year":"1993","unstructured":"Buxton D.; Toxoplasmosis: the first commercial vaccine. Parasitol Today [Regul Ed] 1993,9(9),335-337","journal-title":"Parasitol Today [Regul Ed]"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1201\/9781420092370","author":"Dubey J.P.","year":"2016","unstructured":"Dubey J.P.; Toxoplasmosis of animals and humans 2016","journal-title":"Toxoplasmosis of animals and humans"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(85)90226-0","volume":"2","author":"Rougier D.","year":"1985","unstructured":"Rougier D.; Ambroise-Thomas P.; Detection of toxoplasmic immunity by multipuncture skin test with excretory-secretory antigen. Lancet 1985,2(8447),121-123","journal-title":"Lancet"},{"key":"ref=17","first-page":"220","volume":"22","author":"Daryani A.","year":"2013","unstructured":"Daryani A.; Toxoplasma Gondii: A Review of Excretory Secretory Antigens. Majallah-i Danishgah-i Ulum-i Pizishki-i Mazandaran 2013,22(2),220-232","journal-title":"Majallah-i Danishgah-i Ulum-i Pizishki-i Mazandaran"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0020-7519(01)00261-2","volume":"31","author":"Lekutis C.","year":"2001","unstructured":"Lekutis C.; Ferguson D.J.; Grigg M.E.; Camps M.; Boothroyd J.C.; Surface antigens of Toxoplasma gondii: variations on a theme. Int J Parasitol 2001,31(12),1285-1292","journal-title":"Int J Parasitol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cimid.2014.10.003","volume":"37","author":"Norouzpour Deilami K.","year":"2014","unstructured":"Norouzpour Deilami K.; Daryani A.; Ahmadpour E.; Excretory-secretory antigens: a suitable candidate for immunization against ocular toxoplasmosis in a murine model. Comp Immunol Microbiol Infect Dis 2014,37(5-6),369-374","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.exppara.2008.07.015","volume":"120","author":"Costa-Silva T.A.","year":"2008","unstructured":"Costa-Silva T.A.; Meira C.S.; Ferreira I.M.; Hiramoto R.M.; Pereira-Chioccola V.L.; Evaluation of immunization with tachyzoite excreted-secreted proteins in a novel susceptible mouse model (A\/Sn) for Toxoplasma gondii. Exp Parasitol 2008,120(3),227-234","journal-title":"Exp Parasitol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0304-4017(03)00044-X","volume":"113","author":"Daryani A.","year":"2003","unstructured":"Daryani A.; Hosseini A.Z.; Dalimi A.; Immune responses against excreted\/secreted antigens of Toxoplasma gondii tachyzoites in the murine model. Vet Parasitol 2003,113(2),123-134","journal-title":"Vet Parasitol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/B978-0-323-39981-4.00012-9","author":"Marasini N.","year":"2017","unstructured":"Marasini N.; Liposomes as a vaccine delivery systemMicro and Nanotechnology in Vaccine Development 2017,221-239","journal-title":"Liposomes as a vaccine delivery systemMicro and Nanotechnology in Vaccine Development"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14760584.2017.1306440","volume":"16","author":"Chauhan N.","year":"2017","unstructured":"Chauhan N.; Tiwari S.; Iype T.; Jain U.; An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators. Expert Rev Vaccines 2017,16(5),491-502","journal-title":"Expert Rev Vaccines"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1080\/1061186X.2018.1547734","volume":"27","author":"Yu R.","year":"2019","unstructured":"Yu R.; Mai Y.; Zhao Y.; Hou Y.; Liu Y.; Yang J.; Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy. J Drug Target 2019,27(7),780-789","journal-title":"J Drug Target"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10103-013-1399-x","volume":"29","author":"Shakeri-Zadeh A.","year":"2014","unstructured":"Shakeri-Zadeh A.; Kamrava S.K.; Farhadi M.; Hajikarimi Z.; Maleki S.; Ahmadi A.; A scientific paradigm for targeted nanophotothermolysis; the potential for nanosurgery of cancer. Lasers Med Sci 2014,29(2),847-853","journal-title":"Lasers Med Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","volume":"64","author":"Wilczewska A.Z.","year":"2012","unstructured":"Wilczewska A.Z.; Niemirowicz K.; Markiewicz K.H.; Car H.; Nanoparticles as drug delivery systems. Pharmacol Rep 2012,64(5),1020-1037","journal-title":"Pharmacol Rep"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.nano.2019.02.017","volume":"18","author":"Barabadi H.","year":"2019","unstructured":"Barabadi H.; Alizadeh Z.; Rahimi M.T.; Nanobiotechnology as an emerging approach to combat malaria: A systematic review. Nanomedicine (Lond) 2019,18,221-233","journal-title":"Nanomedicine (Lond)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"Patra J.K.","year":"2018","unstructured":"Patra J.K.; Das G.; Fraceto L.F.; Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 2018,16(1),71","journal-title":"J Nanobiotechnology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cocis.2010.12.004","volume":"16","author":"Zasadzinski J.A.","year":"2011","unstructured":"Zasadzinski J.A.; Wong B.; Forbes N.; Braun G.; Wu G.; Novel methods of enhanced retention in and rapid, targeted release from liposomes. Curr Opin Colloid Interface Sci 2011,16(3),203-214","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/17425247.2012.666968","volume":"9","author":"Rahimpour Y.","year":"2012","unstructured":"Rahimpour Y.; Hamishehkar H.; Liposomes in cosmeceutics. Expert Opin Drug Deliv 2012,9(4),443-455","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jconrel.2010.02.012","volume":"144","author":"Anderson L.J.","year":"2010","unstructured":"Anderson L.J.; Hansen E.; Lukianova-Hleb E.Y.; Hafner J.H.; Lapotko D.O.; Optically guided controlled release from liposomes with tunable plasmonic nanobubbles. J Control Release 2010,144(2),151-158","journal-title":"J Control Release"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0076-6879(09)64014-3","volume":"464","author":"Wu G.","year":"2009","unstructured":"Wu G.; Mikhailovsky A.; Khant H.A.; Zasadzinski J.A.; Chapter 14 - Synthesis, characterization, and optical response of gold nanoshells used to trigger release from liposomes. Methods Enzymol 2009,464,279-307","journal-title":"Methods Enzymol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/0024-3205(80)90268-4","volume":"26","author":"Mezei M.","year":"1980","unstructured":"Mezei M.; Gulasekharam V.; Liposomes--a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980,26(18),1473-1477","journal-title":"Life Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bios.2016.01.090","volume":"80","author":"Alizadeh-Ghodsi M.","year":"2016","unstructured":"Alizadeh-Ghodsi M.; Zavari-Nematabad A.; Hamishehkar H.; Design and development of PCR-free highly sensitive electrochemical assay for detection of telomerase activity using Nano-based (liposomal) signal amplification platform. Biosens Bioelectron 2016,80,426-432","journal-title":"Biosens Bioelectron"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.drudis.2011.04.006","volume":"16","author":"De Temmerman M-L.","year":"2011","unstructured":"De Temmerman M-L.; Rejman J.; Demeester J.; Irvine D.J.; Gander B.; De Smedt S.C.; Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 2011,16(13-14),569-582","journal-title":"Drug Discov Today"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5482087","author":"Bernasconi V","year":"2016","unstructured":"Bernasconi V; Mucosal vaccine development based on liposome technology 2016","journal-title":"Mucosal vaccine development based on liposome technology"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.5772\/50022","author":"Bartova E.","year":"2012","unstructured":"Bartova E.; Sedlak K.; Toxoplasmosis in Animals in the Czech Republic-The Last 10 Years 2012","journal-title":"Toxoplasmosis in Animals in the Czech Republic-The Last 10 Years"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.apjtm.2017.07.013","volume":"10","author":"Shokri A.","year":"2017","unstructured":"Shokri A.; Sharif M.; Teshnizi S.H.; Birds and poultries toxoplasmosis in Iran: A systematic review and meta-analysis. Asian Pac J Trop Med 2017,10(7),635-642","journal-title":"Asian Pac J Trop Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1550-7408.2008.00345.x","volume":"55","author":"Dubey J.P.","year":"2008","unstructured":"Dubey J.P.; The history of Toxoplasma gondii--the first 100 years. J Eukaryot Microbiol 2008,55(6),467-475","journal-title":"J Eukaryot Microbiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1128\/EC.3.4.992-1003.2004","volume":"3","author":"Dzierszinski F.","year":"2004","unstructured":"Dzierszinski F.; Nishi M.; Ouko L.; Roos D.S.; Dynamics of Toxoplasma gondii differentiation. Eukaryot Cell 2004,3(4),992-1003","journal-title":"Eukaryot Cell"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.4102\/ojvr.v82i1.823","author":"Rahimi MT","year":"2015","unstructured":"Rahimi MT; Cats and Toxoplasma gondii: A systematic review and meta-analysis in Iran 2015","journal-title":"Cats and Toxoplasma gondii: A systematic review and meta-analysis in Iran"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"882","DOI":"10.2307\/3284034","volume":"81","author":"Davis S.W.","year":"1995","unstructured":"Davis S.W.; Dubey J.P.; Mediation of immunity to Toxoplasma gondii oocyst shedding in cats. J Parasitol 1995,81(6),882-886","journal-title":"J Parasitol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.vetpar.2004.09.005","volume":"126","author":"Dubey J.P.","year":"2004","unstructured":"Dubey J.P.; Toxoplasmosis - a waterborne zoonosis. Vet Parasitol 2004,126(1-2),57-72","journal-title":"Vet Parasitol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0463.2009.02453.x","volume":"117","author":"Blader I.J.","year":"2009","unstructured":"Blader I.J.; Saeij J.P.; Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS 2009,117(5-6),458-476","journal-title":"APMIS"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ijpara.2003.12.009","volume":"34","author":"Kim K.","year":"2004","unstructured":"Kim K.; Weiss L.M.; Toxoplasma gondii: the model apicomplexan. Int J Parasitol 2004,34(3),423-432","journal-title":"Int J Parasitol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1128\/CMR.11.2.267","volume":"11","author":"Dubey J.P.","year":"1998","unstructured":"Dubey J.P.; Lindsay D.S.; Speer C.A.; Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998,11(2),267-299","journal-title":"Clin Microbiol Rev"},{"key":"ref=47","author":"Webster J.P.","year":"2010","unstructured":"Webster J.P.; Dubey, JP Toxoplasmosis of Animals and Humans 2010","journal-title":"Dubey, JP Toxoplasmosis of Animals and Humans"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4269\/ajtmh.2010.10-0082","volume":"83","author":"Sroka S.","year":"2010","unstructured":"Sroka S.; Bartelheimer N.; Winter A.; Prevalence and risk factors of toxoplasmosis among pregnant women in Fortaleza, Northeastern Brazil. Am J Trop Med Hyg 2010,83(3),528-533","journal-title":"Am J Trop Med Hyg"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3109\/00365548.2012.693197","volume":"44","author":"Saadatnia G.","year":"2012","unstructured":"Saadatnia G.; Golkar M.; A review on human toxoplasmosis. Scand J Infect Dis 2012,44(11),805-814","journal-title":"Scand J Infect Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/1995-7645.250341","volume":"12","author":"Ahmadpour E.","year":"2019","unstructured":"Ahmadpour E.; Diagnosis of Toxoplasma gondii infection in pregnant women using automated chemiluminescence and quantitative real time PCR. Asian Pac J Trop Med 2019,12(1),26","journal-title":"Asian Pac J Trop Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.diagmicrobio.2014.02.014","volume":"79","author":"Fallahi S.","year":"2014","unstructured":"Fallahi S.; Seyyed Tabaei S.J.; Pournia Y.; Zebardast N.; Kazemi B.; Comparison of loop-mediated isothermal amplification (LAMP) and nested-PCR assay targeting the RE and B1 gene for detection of Toxoplasma gondii in blood samples of children with leukaemia. Diagn Microbiol Infect Dis 2014,79(3),347-354","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/651266","volume":"50","author":"Meers S.","year":"2010","unstructured":"Meers S.; Lagrou K.; Theunissen K.; Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis 2010,50(8),1127-1134","journal-title":"Clin Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0169-4758(93)90038-H","volume":"9","author":"Ambroise-Thomas P.","year":"1993","unstructured":"Ambroise-Thomas P.; Pelloux H.; Toxoplasmosis - congenital and in immunocompromised patients: a parallel. Parasitol Today [Regul Ed] 1993,9(2),61-63","journal-title":"Parasitol Today [Regul Ed]"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00002030-199006000-00004","volume":"4","author":"Grant I.H.","year":"1990","unstructured":"Grant I.H.; Gold J.W.; Rosenblum M.; Niedzwiecki D.; Armstrong D.; Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990,4(6),519-521","journal-title":"AIDS"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10096-008-0600-9","volume":"28","author":"Machala L.","year":"2009","unstructured":"Machala L.; Mal\u00fd M.; Hrd\u00e1 S.; Rozsypal H.; Stankov\u00e1 M.; Kodym P.; Antibody response of HIV-infected patients to latent, cerebral and recently acquired toxoplasmosis. Eur J Clin Microbiol Infect Dis 2009,28(2),179-182","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00006254-200105000-00025","volume":"56","author":"Jones J.L.","year":"2001","unstructured":"Jones J.L.; Lopez A.; Wilson M.; Schulkin J.; Gibbs R.; Congenital toxoplasmosis: a review. Obstet Gynecol Surv 2001,56(5),296-305","journal-title":"Obstet Gynecol Surv"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ajo.2003.09.040","volume":"136","author":"Holland G.N.","year":"2003","unstructured":"Holland G.N.; Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003,136(6),973-988","journal-title":"Am J Ophthalmol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000310765","volume":"211","author":"Bornand J-E.","year":"1997","unstructured":"Bornand J-E.; de Gottrau P.; Uveitis: is ocular toxoplasmosis only a clinical diagnosis? Ophthalmologica 1997,211(2),87-89","journal-title":"Ophthalmologica"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0002-9394(01)01211-9","volume":"133","author":"Song A.","year":"2002","unstructured":"Song A.; Scott I.U.; Davis J.L.; Lam B.L.; Atypical anterior optic neuropathy caused by toxoplasmosis. Am J Ophthalmol 2002,133(1),162-164","journal-title":"Am J Ophthalmol"},{"key":"ref=60","first-page":"68","volume":"24","author":"Moreno R.J.","year":"1992","unstructured":"Moreno R.J.; Weisman J.; Waller S.; Neuroretinitis: an unusual presentation of ocular toxoplasmosis. Ann Ophthalmol 1992,24(2),68-70","journal-title":"Ann Ophthalmol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00006982-199717040-00013","volume":"17","author":"Hayashi S.","year":"1997","unstructured":"Hayashi S.; Kim M.K.; Belfort R.; White-centered retinal hemorrhages in ocular toxoplasmosis. Retina 1997,17(4),351-352","journal-title":"Retina"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11940-003-0018-8","volume":"5","author":"Nath A.","year":"2003","unstructured":"Nath A.; Sinai A.P.; Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003,5(1),3-12","journal-title":"Curr Treat Options Neurol"},{"key":"ref=63","volume":"Vol. 34","author":"Minagar A.","year":"2016","unstructured":"Minagar A.; Finney G.; Heilman K.M.; Neurobehavioral manifestations of neurological diseases: diagnosis 2016,Vol. 34","journal-title":"Neurobehavioral manifestations of neurological diseases: diagnosis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/INF.0b013e3181b20ed1","volume":"29","author":"Robert-Gangneux F.","year":"2010","unstructured":"Robert-Gangneux F.; Dupretz P.; Yvenou C.; Clinical relevance of placenta examination for the diagnosis of congenital toxoplasmosis. Pediatr Infect Dis J 2010,29(1),33-38","journal-title":"Pediatr Infect Dis J"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/IAI.58.7.2120-2126.1990","volume":"58","author":"Duquesne V.","year":"1990","unstructured":"Duquesne V.; Auriault C.; Darcy F.; Decavel J.P.; Capron A.; Protection of nude rats against Toxoplasma infection by excreted-secreted antigen-specific helper T cells. Infect Immun 1990,58(7),2120-2126","journal-title":"Infect Immun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0001-706X(01)00201-7","volume":"81","author":"Carruthers V.B.","year":"2002","unstructured":"Carruthers V.B.; Host cell invasion by the opportunistic pathogen Toxoplasma gondii. Acta Trop 2002,81(2),111-122","journal-title":"Acta Trop"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2013.06.005","volume":"395","author":"Meira C.S.","year":"2013","unstructured":"Meira C.S.; Vidal J.E.; Costa-Silva T.A.; IgG4 specific to Toxoplasma gondii excretory\/secretory antigens in serum and\/or cerebrospinal fluid support the cerebral toxoplasmosis diagnosis in HIV-infected patients. J Immunol Methods 2013,395(1-2),21-28","journal-title":"J Immunol Methods"},{"key":"ref=68","first-page":"78","volume":"3","author":"Daryani A.","year":"2006","unstructured":"Daryani A.; Protective role of antigens from peritoneal exudates of infected mice against toxoplasmosis. Iran J Immunol 2006,3(2),78-85","journal-title":"Iran J Immunol"},{"journal-title":"Bacterial production of dense granule antigen GRA8 of Toxoplasma gondii","year":"2009","key":"ref=69","unstructured":"Bacterial production of dense granule antigen GRA8 of Toxoplasma gondii BABAEI2009"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.3347\/kjp.2009.47.S.S29","volume":"47","author":"Nam H-W.","year":"2009","unstructured":"Nam H-W.; GRA proteins of Toxoplasma gondii: maintenance of host-parasite interactions across the parasitophorous vacuolar membrane. Korean J Parasitol 2009,47(Suppl.),S29-S37","journal-title":"Korean J Parasitol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.exppara.2014.05.008","volume":"143","author":"Daryani A.","year":"2014","unstructured":"Daryani A.; Sharif M.; Dadimoghaddam Y.; Determination of parasitic load in different tissues of murine toxoplasmosis after immunization by excretory-secretory antigens using Real time QPCR. Exp Parasitol 2014,143,55-59","journal-title":"Exp Parasitol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.2174\/1381612822666160217125028","volume":"22","author":"Jaimes-Aguirre L.","year":"2016","unstructured":"Jaimes-Aguirre L.; Gibbens-Bandala B.V.; Morales-Avila E.; Ocampo-Garc\u00eda B.E.; Seyedeh-Fatemeh M.; Amirhosein A.; Polymer-based drug delivery systems, development and pre-clinical status. Curr Pharm Des 2016,22(19),2886-2903","journal-title":"Curr Pharm Des"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijpharm.2005.02.032","volume":"296","author":"Betz G.","year":"2005","unstructured":"Betz G.; Aeppli A.; Menshutina N.; Leuenberger H.; In vivo comparison of various liposome formulations for cosmetic application. Int J Pharm 2005,296(1-2),44-54","journal-title":"Int J Pharm"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000086666","volume":"18","author":"Choi M.J.","year":"2005","unstructured":"Choi M.J.; Maibach H.I.; Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005,18(5),209-219","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0169-409X(90)90021-J","volume":"5","author":"Egbaria K.","year":"1990","unstructured":"Egbaria K.; Weiner N.; Liposomes as a topical drug delivery system. Adv Drug Deliv Rev 1990,5(3),287-300","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11095-010-0073-2","volume":"27","author":"Filipe V.","year":"2010","unstructured":"Filipe V.; Hawe A.; Jiskoot W.; Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010,27(5),796-810","journal-title":"Pharm Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/08982100903161449","volume":"20","author":"Jain B.","year":"2010","unstructured":"Jain B.; Singh B.; Katare O.P.; Vyas S.P.; Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res 2010,20(2),105-114","journal-title":"J Liposome Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/17425247.5.2.235","volume":"5","author":"Su Y-H.","year":"2008","unstructured":"Su Y-H.; Fang J-Y.; Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008,5(2),235-249","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jconrel.2004.11.020","volume":"103","author":"Sinico C.","year":"2005","unstructured":"Sinico C.; Manconi M.; Peppi M.; Lai F.; Valenti D.; Fadda A.M.; Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release 2005,103(1),123-136","journal-title":"J Control Release"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1042\/bj1860591","volume":"186","author":"Kirby C.","year":"1980","unstructured":"Kirby C.; Clarke J.; Gregoriadis G.; Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980,186(2),591-598","journal-title":"Biochem J"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0001-8686(94)00223-Y","volume":"54","author":"Jones M.N.","year":"1995","unstructured":"Jones M.N.; The surface properties of phospholipid liposome systems and their characterisation. Adv Colloid Interface Sci 1995,54,93-128","journal-title":"Adv Colloid Interface Sci"},{"author":"Rahimpour Y","key":"ref=82","unstructured":"Rahimpour Y; Hamishehkar H; Nokhodchi A; A. Lipidic micro and nano carriers for pulmonary drug delivery\u2014a state of the art review. pulmonary drug delivery: Advances and Challenges 2015; pp. 123-42."},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-3-642-00477-3_4","author":"Souto E.B.","year":"2010","unstructured":"Souto E.B.; M\u00fcller R.H.; Lipid nanoparticles: effect on bioavailability and pharmacokinetic changesDrug delivery 2010,115-141","journal-title":"Lipid nanoparticles: effect on bioavailability and pharmacokinetic changesDrug delivery"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1517\/17425247.2011.574610","volume":"8","author":"Gonz\u00e1lez-Rodr\u00edguez M.L.","year":"2011","unstructured":"Gonz\u00e1lez-Rodr\u00edguez M.L.; Rabasco A.M.; Charged liposomes as carriers to enhance the permeation through the skin. Expert Opin Drug Deliv 2011,8(7),857-871","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/17425247.2.1.75","volume":"2","author":"Jaspart S.","year":"2005","unstructured":"Jaspart S.; Piel G.; Delattre L.; Evrard B.; Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv 2005,2(1),75-87","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.arr.2007.08.006","volume":"6","author":"Kaur I.P.","year":"2007","unstructured":"Kaur I.P.; Kapila M.; Agrawal R.; Role of novel delivery systems in developing topical antioxidants as therapeutics to combat photoageing. Ageing Res Rev 2007,6(4),271-288","journal-title":"Ageing Res Rev"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3109\/10837450902911937","volume":"14","author":"Viriyaroj A.","year":"2009","unstructured":"Viriyaroj A.; Ngawhirunpat T.; Sukma M.; Akkaramongkolporn P.; Ruktanonchai U.; Opanasopit P.; Physicochemical properties and antioxidant activity of gamma-oryzanol-loaded liposome formulations for topical use. Pharm Dev Technol 2009,14(6),665-671","journal-title":"Pharm Dev Technol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10544-011-9590-y","volume":"14","author":"Celia C.","year":"2012","unstructured":"Celia C.; Cilurzo F.; Trapasso E.; Cosco D.; Fresta M.; Paolino D.; Ethosomes and transfersomes containing linoleic acid: physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomed Microdevices 2012,14(1),119-130","journal-title":"Biomed Microdevices"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/08982100802465941","volume":"18","author":"Mozafari M.R.","year":"2008","unstructured":"Mozafari M.R.; Johnson C.; Hatziantoniou S.; Demetzos C.; Nanoliposomes and their applications in food nanotechnology. J Liposome Res 2008,18(4),309-327","journal-title":"J Liposome Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.trac.2005.07.006","volume":"25","author":"Gomez-Hens A.","year":"2006","unstructured":"Gomez-Hens A.; Fernandez-Romero J.; Analytical methods for the control of liposomal delivery systems. Trends Analyt Chem 2006,25(2),167-178","journal-title":"Trends Analyt Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"11808","DOI":"10.1039\/c2jm31675g","volume":"22","author":"Tao Y.","year":"2012","unstructured":"Tao Y.; Han J.; Dou H.; Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study. J Mater Chem 2012,22(23),11808-11815","journal-title":"J Mater Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1073\/pnas.77.10.6105","volume":"77","author":"Hale A.H.","year":"1980","unstructured":"Hale A.H.; Ruebush M.J.; Lyles D.S.; Harris D.T.; Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1980,77(10),6105-6108","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/0014-4827(89)90094-3","volume":"181","author":"Bogdanov A.A.","year":"1989","unstructured":"Bogdanov A.A.; Gordeeva L.V.; Torchilin V.P.; Margolis L.B.; Lectin-bearing liposomes: differential binding to normal and to transformed mouse fibroblasts. Exp Cell Res 1989,181(2),362-374","journal-title":"Exp Cell Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.018","volume":"294","author":"Zhang N.","year":"2005","unstructured":"Zhang N.; Ping Q.N.; Huang G.H.; Xu W.F.; Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int J Pharm 2005,294(1-2),247-259","journal-title":"Int J Pharm"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.colsurfa.2012.01.035","volume":"397","author":"Yoshino K.","year":"2012","unstructured":"Yoshino K.; Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes. Colloids Surf A Physicochem Eng Asp 2012,397,73-79","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2004.06.010","volume":"99","author":"Ghafourian T.","year":"2004","unstructured":"Ghafourian T.; Zandasrar P.; Hamishekar H.; Nokhodchi A.; The effect of penetration enhancers on drug delivery through skin: a QSAR study. J Control Release 2004,99(1),113-125","journal-title":"J Control Release"},{"key":"ref=97","first-page":"14","volume":"3","author":"Dua J.","year":"2012","unstructured":"Dua J.; Rana A.; Bhandari A.; Liposome: methods of preparation and applications. Int J Pharm Stud Res 2012,3(2),14-20","journal-title":"Int J Pharm Stud Res"},{"key":"ref=98","first-page":"65","volume":"9","author":"Riaz M.","year":"1996","unstructured":"Riaz M.; Liposomes preparation methods. Pak J Pharm Sci 1996,9(1),65-77","journal-title":"Pak J Pharm Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1468-3083.2009.03100.x","volume":"23","author":"de Leeuw J.","year":"2009","unstructured":"de Leeuw J.; de Vijlder H.C.; Bjerring P.; Neumann H.A.; Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009,23(5),505-516","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/863734","author":"Mishra GP","year":"2011","unstructured":"Mishra GP; Recent applications of liposomes in ophthalmic drug delivery 2011","journal-title":"Recent applications of liposomes in ophthalmic drug delivery"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0378-5173(97)00135-X","volume":"154","author":"Sharma A.","year":"1997","unstructured":"Sharma A.; Sharma U.S.; Liposomes in drug delivery: progress and limitations. Int J Pharm 1997,154(2),123-140","journal-title":"Int J Pharm"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.5101\/nbe.v3i1.p1-16","volume":"3","author":"Zhang Y.","year":"2011","unstructured":"Zhang Y.; Relationship between Size and Function of Natural Substance Particles. Nano Biomed Eng 2011,3(1)","journal-title":"Nano Biomed Eng"},{"key":"ref=103","first-page":"711","volume":"10","author":"Mozafari M.R.","year":"2005","unstructured":"Mozafari M.R.; Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005,10(4),711-719","journal-title":"Cell Mol Biol Lett"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0009-3084(86)90077-0","volume":"40","author":"Mayer L.D.","year":"1986","unstructured":"Mayer L.D.; Bally M.B.; Hope M.J.; Cullis P.R.; Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 1986,40(2-4),333-345","journal-title":"Chem Phys Lipids"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0168-3659(97)00261-7","volume":"53","author":"Gabizon A.","year":"1998","unstructured":"Gabizon A.; Goren D.; Cohen R.; Barenholz Y.; Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998,53(1-3),275-279","journal-title":"J Control Release"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"Akbarzadeh A.","year":"2013","unstructured":"Akbarzadeh A.; Rezaei-Sadabady R.; Davaran S.; Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013,8(1),102","journal-title":"Nanoscale Res Lett"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/0005-2736(77)90028-1","volume":"464","author":"Steger L.D.","year":"1977","unstructured":"Steger L.D.; Desnick R.J.; Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim Biophys Acta 1977,464(3),530-546","journal-title":"Biochim Biophys Acta"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0022-2275(20)41300-8","volume":"19","author":"Finkelstein M.","year":"1978","unstructured":"Finkelstein M.; Weissmann G.; The introduction of enzymes into cells by means of liposomes. J Lipid Res 1978,19(3),289-303","journal-title":"J Lipid Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3892\/ijo.17.2.309","volume":"17","author":"Kubo T.","year":"2000","unstructured":"Kubo T.; Sugita T.; Shimose S.; Nitta Y.; Ikuta Y.; Murakami T.; Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 2000,17(2),309-315","journal-title":"Int J Oncol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/187152006778699095","volume":"6","author":"Minko T.","year":"2006","unstructured":"Minko T.; Pakunlu R.I.; Wang Y.; Khandare J.J.; Saad M.; New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 2006,6(6),537-552","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.vaccine.2011.10.103","volume":"30","author":"Dong L.","year":"2012","unstructured":"Dong L.; Liu F.; Fairman J.; Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine 2012,30(2),254-264","journal-title":"Vaccine"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/erv.11.17","volume":"10","author":"Christensen D.","year":"2011","unstructured":"Christensen D.; Korsholm K.S.; Andersen P.; Agger E.M.; Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2011,10(4),513-521","journal-title":"Expert Rev Vaccines"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"Peer D.","year":"2007","unstructured":"Peer D.; Karp J.M.; Hong S.; Farokhzad O.C.; Margalit R.; Langer R.; Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007,2(12),751-760","journal-title":"Nat Nanotechnol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/anie.200604295","volume":"46","author":"Liu Z.","year":"2007","unstructured":"Liu Z.; Winters M.; Holodniy M.; Dai H.; siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl 2007,46(12),2023-2027","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2005.03.020","volume":"105","author":"Kunisawa J.","year":"2005","unstructured":"Kunisawa J.; Masuda T.; Katayama K.; Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release 2005,105(3),344-353","journal-title":"J Control Release"},{"key":"ref=116","first-page":"13","volume":"2","author":"S\u00fcleymanoglu E.","year":"2004","unstructured":"S\u00fcleymanoglu E.; A nanoscale polynucleotide-neutral liposome self-assemblies formulated for therapeutic gene delivery. Electron J Biomed 2004,2,13-35","journal-title":"Electron J Biomed"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.addr.2011.05.018","volume":"63","author":"Pal I.","year":"2011","unstructured":"Pal I.; Ramsey J.D.; The role of the lymphatic system in vaccine trafficking and immune response. Adv Drug Deliv Rev 2011,63(10-11),909-922","journal-title":"Adv Drug Deliv Rev"},{"journal-title":"Liposomes for Inhalation","author":"Ong HX","key":"ref=118","unstructured":"Ong HX; Traini D; Young PM; Liposomes for Inhalation"},{"key":"ref=119","first-page":"247","volume":"11","author":"Zhang X-Y.","year":"2014","unstructured":"Zhang X-Y.; Lu W-Y.; Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med 2014,11(4),247-254","journal-title":"Cancer Biol Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.biomaterials.2016.01.006","volume":"83","author":"Da Silva C.G.","year":"2016","unstructured":"Da Silva C.G.; Rueda F.; L\u00f6wik C.W.; Ossendorp F.; Cruz L.J.; Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials 2016,83,308-320","journal-title":"Biomaterials"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/21645515.2016.1256518","volume":"13","author":"Tyagi R.K.","year":"2017","unstructured":"Tyagi R.K.; Parmar R.; Patel N.; A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma. Hum Vaccin Immunother 2017,13(4),854-866","journal-title":"Hum Vaccin Immunother"},{"author":"Riether C","key":"ref=122","doi-asserted-by":"publisher","unstructured":"Riether C; Sch\u00fcrch C; Ochsenbein AF; From \u201cmagic bullets\u201d to specific cancer immunotherapy. Swiss Med Wkly 2013; 143w13734","DOI":"10.4414\/smw.2013.13734"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2012.05.010","volume":"161","author":"Joshi M.D.","year":"2012","unstructured":"Joshi M.D.; Unger W.J.; Storm G.; van Kooyk Y.; Mastrobattista E.; Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 2012,161(1),25-37","journal-title":"J Control Release"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/eji.201546023","volume":"46","author":"Chiang M.C.","year":"2016","unstructured":"Chiang M.C.; Tullett K.M.; Lee Y.S.; Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Eur J Immunol 2016,46(2),329-339","journal-title":"Eur J Immunol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/nnm.13.66","volume":"9","author":"Cruz L.J.","year":"2014","unstructured":"Cruz L.J.; Rueda F.; Sim\u00f3n L.; Cordobilla B.; Albericio F.; Domingo J.C.; Liposomes containing NY-ESO-1\/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine (Lond) 2014,9(4),435-449","journal-title":"Nanomedicine (Lond)"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2016.05.008","volume":"233","author":"Shen K-Y.","year":"2016","unstructured":"Shen K-Y.; Liu H.Y.; Li H.J.; A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity. J Control Release 2016,233,57-63","journal-title":"J Control Release"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2326-6066.CIR-16-0283","volume":"5","author":"Varypataki E.M.","year":"2017","unstructured":"Varypataki E.M.; Benne N.; Bouwstra J.; Jiskoot W.; Ossendorp F.; Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines. Cancer Immunol Res 2017,5(3),222-233","journal-title":"Cancer Immunol Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.imlet.2016.05.016","volume":"176","author":"Alipour Talesh G.","year":"2016","unstructured":"Alipour Talesh G.; Ebrahimi Z.; Badiee A.; Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol Lett 2016,176,57-64","journal-title":"Immunol Lett"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.actbio.2017.01.072","volume":"53","author":"Klauber T.C.B.","year":"2017","unstructured":"Klauber T.C.B.; Laursen J.M.; Zucker D.; Brix S.; Jensen S.S.; Andresen T.L.; Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines. Acta Biomater 2017,53,367-377","journal-title":"Acta Biomater"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jconrel.2013.07.004","volume":"171","author":"Nakamura T.","year":"2013","unstructured":"Nakamura T.; Yamazaki D.; Yamauchi J.; Harashima H.; The nanoparticulation by octaarginine-modified liposome improves \u03b1-galactosylceramide-mediated antitumor therapy via systemic administration. J Control Release 2013,171(2),216-224","journal-title":"J Control Release"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrneurol.2010.112","volume":"6","author":"Comabella M.","year":"2010","unstructured":"Comabella M.; Montalban X.; M\u00fcnz C.; L\u00fcnemann J.D.; Targeting dendritic cells to treat multiple sclerosis. Nat Rev Neurol 2010,6(9),499-507","journal-title":"Nat Rev Neurol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molmed.2009.04.003","volume":"15","author":"Ahlers J.D.","year":"2009","unstructured":"Ahlers J.D.; Belyakov I.M.; Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines. Trends Mol Med 2009,15(6),263-274","journal-title":"Trends Mol Med"},{"key":"ref=133","first-page":"4545","volume":"102","author":"Jeong H.S.","year":"2014","unstructured":"Jeong H.S.; Na K.S.; Hwang H.; Effect of space length of mannose ligand on uptake of mannosylated liposome in RAW 264.7 cells: In vitro and in vivo studies. J Biomed Mater Res A 2014,102(12),4545-4553","journal-title":"J Biomed Mater Res A"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2009.12.016","volume":"149","author":"Wijagkanalan W.","year":"2011","unstructured":"Wijagkanalan W.; Kawakami S.; Higuchi Y.; Yamashita F.; Hashida M.; Intratracheally instilled mannosylated cationic liposome\/NF\u03baB decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release 2011,149(1),42-50","journal-title":"J Control Release"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1753425916636671","volume":"22","author":"Patin E.C.","year":"2016","unstructured":"Patin E.C.; Willcocks S.; Orr S.; Ward T.H.; Lang R.; Schaible U.E.; Mincle-mediated anti-inflammatory IL-10 response counter-regulates IL-12 in vitro. Innate Immun 2016,22(3),181-185","journal-title":"Innate Immun"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00401-014-1310-2","volume":"128","author":"Bogie J.F.","year":"2014","unstructured":"Bogie J.F.; Stinissen P.; Hendriks J.J.; Macrophage subsets and microglia in multiple sclerosis. Acta Neuropathol 2014,128(2),191-213","journal-title":"Acta Neuropathol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/1352458517698759","volume":"24","author":"Bogie J.F.","year":"2018","unstructured":"Bogie J.F.; Boelen E.; Louagie E.; CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis. Mult Scler 2018,24(3),290-300","journal-title":"Mult Scler"},{"key":"ref=138","author":"Gernez Y.","year":"2010","unstructured":"Gernez Y.; Tirouvanziam R.; Chanez P.; Neutrophils in chronic inflammatory airway diseases: can we target them and how? 2010","journal-title":"Neutrophils in chronic inflammatory airway diseases: can we target them and how?"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.bcp.2013.09.023","volume":"86","author":"Inoh Y.","year":"2013","unstructured":"Inoh Y.; Tadokoro S.; Tanabe H.; Inhibitory effects of a cationic liposome on allergic reaction mediated by mast cell activation. Biochem Pharmacol 2013,86(12),1731-1738","journal-title":"Biochem Pharmacol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4049\/jimmunol.0904013","volume":"184","author":"Schoenen H.","year":"2010","unstructured":"Schoenen H.; Bodendorfer B.; Hitchens K.; Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010,184(6),2756-2760","journal-title":"J Immunol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","volume":"32","author":"van Dissel J.T.","year":"2014","unstructured":"van Dissel J.T.; Joosten S.A.; Hoff S.T.; A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 2014,32(52),7098-7107","journal-title":"Vaccine"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/erv.11.29","volume":"10","author":"Gar\u00e7on N.","year":"2011","unstructured":"Gar\u00e7on N.; Van Mechelen M.; Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011,10(4),471-486","journal-title":"Expert Rev Vaccines"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"39475","DOI":"10.1038\/srep39475","volume":"6","author":"Detienne S.","year":"2016","unstructured":"Detienne S.; Welsby I.; Collignon C.; Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep 2016,6,39475","journal-title":"Sci Rep"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"Chlibek R.","year":"2013","unstructured":"Chlibek R.; Bayas J.M.; Collins H.; Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis 2013,208(12),1953-1961","journal-title":"J Infect Dis"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"Rts S.","year":"2015","unstructured":"Rts S.; Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015,386(9988),31-45","journal-title":"Lancet"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/infdis\/jiw237","volume":"214","author":"Regules J.A.","year":"2016","unstructured":"Regules J.A.; Cicatelli S.B.; Bennett J.W.; Fractional third and fourth dose of RTS, S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis 2016,214(5),762-771","journal-title":"J Infect Dis"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/0035-9203(85)90122-1","volume":"79","author":"McLeod R.","year":"1985","unstructured":"McLeod R.; Estes R.G.; Mack D.G.; Effects of adjuvants and Toxoplasma gondii antigens on immune response and outcome of peroral T. gondii challenge. Trans R Soc Trop Med Hyg 1985,79(6),800-804","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/IAI.57.1.132-137.1989","volume":"57","author":"Mellors J.W.","year":"1989","unstructured":"Mellors J.W.; Debs R.J.; Ryan J.L.; Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity. Infect Immun 1989,57(1),132-137","journal-title":"Infect Immun"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2307\/3282665","volume":"76","author":"Tachibana H.","year":"1990","unstructured":"Tachibana H.; Yoshihara E.; Kaneda Y.; Nakae T.; Protection of Toxoplasma gondii-infected mice by stearylamine-bearing liposomes. J Parasitol 1990,76(3),352-355","journal-title":"J Parasitol"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.4049\/jimmunol.147.10.3496","volume":"147","author":"B\u00fclow R.","year":"1991","unstructured":"B\u00fclow R.; Boothroyd J.C.; Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. J Immunol 1991,147(10),3496-3500","journal-title":"J Immunol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1590\/S0074-02761999000400010","volume":"94","author":"Elsaid M.M.","year":"1999","unstructured":"Elsaid M.M.; Vitor R.W.; Fr\u00e9zard F.J.; Martins M.S.; Protection against toxoplasmosis in mice immunized with different antigens of Toxoplasma gondii incorporated into liposomes. Mem Inst Oswaldo Cruz 1999,94(4),485-490","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1590\/S0074-02762001000100011","volume":"96","author":"Elsaid M.M.","year":"2001","unstructured":"Elsaid M.M.; Martins M.S.; Fr\u00e9zard F.; Braga E.M.; Vitor R.W.; Vertical toxoplasmosis in a murine model. Protection after immunization with antigens of Toxoplasma gondii incorporated into liposomes. Mem Inst Oswaldo Cruz 2001,96(1),99-104","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=153","first-page":"1561","volume":"116","author":"Chen H.","year":"2003","unstructured":"Chen H.; Chen G.; Zheng H.; Guo H.; Induction of immune responses in mice by vaccination with Liposome-entrapped DNA complexes encoding Toxoplasma gondii SAG1 and ROP1 genes. Chin Med J (Engl) 2003,116(10),1561-1566","journal-title":"Chin Med J (Engl)"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1631\/jzus.B0820300","volume":"10","author":"Chen R.","year":"2009","unstructured":"Chen R.; Lu S.H.; Tong Q.B.; Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondii. J Zhejiang Univ Sci B 2009,10(7),512-521","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref=155","first-page":"118","year":"2012","unstructured":"Medical Helmintology 2012,118-134","journal-title":"Medical Helmintology"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2478\/v10181-011-0107-7","volume":"15","author":"Hiszczy\u0144ska-Sawicka E.","year":"2012","unstructured":"Hiszczy\u0144ska-Sawicka E.; Li H.; Boyu Xu J.; Induction of immune responses in sheep by vaccination with liposome-entrapped DNA complexes encoding Toxoplasma gondii MIC3 gene. Pol J Vet Sci 2012,15(1),3-9","journal-title":"Pol J Vet Sci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.vetpar.2010.11.047","volume":"177","author":"Hiszczy\u0144ska-Sawicka E.","year":"2011","unstructured":"Hiszczy\u0144ska-Sawicka E.; Ol\u0119dzka G.; Holec-G\u0105sior L.; Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii. Vet Parasitol 2011,177(3-4),281-289","journal-title":"Vet Parasitol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.exppara.2014.12.007","volume":"149","author":"El-Zawawy L.A.","year":"2015","unstructured":"El-Zawawy L.A.; El-Said D.; Mossallam S.F.; Ramadan H.S.; Younis S.S.; Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis. Exp Parasitol 2015,149,54-64","journal-title":"Exp Parasitol"},{"key":"ref=159","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2014.09.020","author":"El-Zawawy LA","unstructured":"El-Zawawy LA; El-Said D; Mossallam SF; Ramadan HS; Younis SS; Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii Acta Trop 2015; 141(Pt A): 103-11.","journal-title":"Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.vaccine.2014.01.095","volume":"32","author":"Tanaka S.","year":"2014","unstructured":"Tanaka S.; Kuroda Y.; Ihara F.; Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii. Vaccine 2014,32(16),1781-1785","journal-title":"Vaccine"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.exppara.2016.03.021","volume":"166","author":"Si K.","year":"2016","unstructured":"Si K.; Wei L.; Yu X.; Effects of (+)-usnic acid and (+)-usnic acid-liposome on Toxoplasma gondii. Exp Parasitol 2016,166,68-74","journal-title":"Exp Parasitol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cimid.2018.09.012","volume":"59","author":"Azadi Y.","year":"2018","unstructured":"Azadi Y.; Ahmadpour E.; Hamishehkar H.; Quantification of Toxoplasma gondii in the tissues of BALB\/c mice after immunization with nanoliposomal excretory-secretory antigens using Real-Time PCR. Comp Immunol Microbiol Infect Dis 2018,59,52-56","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/pharmaceutics8010007","volume":"8","author":"Tandrup Schmidt S.","year":"2016","unstructured":"Tandrup Schmidt S.; Foged C.; Korsholm K.S.; Rades T.; Christensen D.; Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics 2016,8(1),7","journal-title":"Pharmaceutics"},{"key":"ref=164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.02.008","author":"Frenz T","unstructured":"Frenz T; Grabski E; Dur\u00e1n V; Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers Eur J Pharm Biopharm 2015; 95(Pt A): 13-7.","journal-title":"Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/1061186X.2013.839684","volume":"22","author":"Ahmadi A.","year":"2014","unstructured":"Ahmadi A.; Arami S.; Potential applications of nanoshells in biomedical sciences. J Drug Target 2014,22(3),175-190","journal-title":"J Drug Target"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:18:44Z","timestamp":1695341924000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176095\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":165,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666191023151423","relation":{},"ISSN":["1389-4501"],"issn-type":[{"type":"print","value":"1389-4501"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}